Oral squamous cell carcinoma, the most common form of head and neck cancer, is confronting researchers with a problem that remains stubbornly difficult: how to destroy tumors without permanently damaging the mouth’s essential functions. Surgery and radiation can save lives, but they may also leave patients with severe impairment in speaking, swallowing, and appearance. With new cases projected to increase by roughly 30% over the next decade, a team at the University of Pennsylvania is testing a nanomedicine strategy designed to attack oral cancer on two biological fronts at once.
The experimental treatment uses lipid nanoparticles, or LNPs, microscopic spheres made from fat-like molecules that can transport therapeutic cargo into cells. The Penn researchers engineered an LNP formulation to deliver messenger RNA encoding the tumor-suppressor protein p53 alongside ciclopirox, an FDA-approved antifungal drug with reported anticancer and immune-modulating activity. Their findings, published in Advanced Materials, indicate that the combined treatment can reduce tumor growth and extend survival in animal models, including models in which tumors resist p53-based therapy.
The rationale for targeting p53 is rooted in the genetics of oral cancer. More than 70% of oral squamous cell carcinoma cases involve mutations in the TP53 gene, which normally produces p53, a protein that helps detect cellular damage and either halt cell division or initiate programmed cell death. When p53 is disabled, abnormal cells can continue multiplying, accumulate additional mutations, and evade mechanisms that would ordinarily eliminate them. Delivering p53 messenger RNA offers a temporary way to instruct tumor cells to produce functional p53 without permanently altering their DNA.
Messenger RNA, however, is fragile and difficult to deliver. It can be rapidly degraded in the body and may fail to enter tumor cells in sufficient quantities. LNPs help solve this problem by packaging the RNA inside a protective structure that can interact with cell membranes and release its cargo after uptake. The Penn team designed a specialized formulation intended to improve delivery into oral cancer cells, a key challenge because the success of an mRNA therapy depends not only on the genetic message but also on whether that message reaches the right cells.
The second component, ciclopirox, gives the approach a complementary mechanism. Rather than relying solely on restoration of a tumor-suppressor pathway, the drug can contribute direct chemotherapeutic effects while also influencing the immune environment surrounding the tumor. The researchers found that p53 and ciclopirox together acted through multiple biological routes, killing cancer cells while making the tumor microenvironment less immunosuppressive. This is important because tumors are not simply masses of malignant cells; they also contain immune cells and signaling networks that can suppress an effective attack.
Among the cells affected may be tumor-associated macrophages, immune cells that can either help eliminate cancer or, under the influence of a tumor, support its growth and shield it from immune destruction. The study suggests that the combined treatment may reprogram these macrophages, shifting them away from a tumor-protective state. The researchers emphasize that the precise mechanism remains unresolved and that the proposed pathway will require further confirmation. Still, the possibility of converting the tumor’s immune surroundings from an obstacle into an ally is central to the platform’s chemoimmunotherapy design.
The treatment may also benefit from the physical accessibility of oral tumors. Because many oral cancers can be reached locally, an LNP-based therapy could potentially be administered in a way that concentrates treatment near the tumor while limiting exposure to healthy tissues. At the same time, local treatment could stimulate a broader immune response capable of recognizing malignant cells elsewhere in the body. That prospect is particularly significant for oral squamous cell carcinoma, which can recur or spread to regional lymph nodes and distant sites. The current work, however, remains preclinical and does not establish that the therapy is safe or effective in people.
In animal experiments, the LNP combination reduced tumor burden and prolonged survival, including in aggressive models described as resistant to p53 therapy. The dual-payload design could be valuable because tumors differ substantially from one patient to another. If one drug encounters a resistance mechanism, the second may continue to act through a separate pathway. Rather than developing a separate treatment for every mutation, the researchers envision a tunable delivery system in which the therapeutic cargo can be adjusted to match the biology of different tumors.
The Penn team plans to refine the nanoparticles to improve targeting and delivery precision, test additional drug combinations, and explore alternative routes of administration. Future studies will also use more complex preclinical models that better reflect the genetic diversity of human tumors. Such work will be essential before clinical testing, particularly because earlier efforts to use p53 as a cancer therapy have often been undermined by tumor heterogeneity and resistance. The researchers say the platform could eventually support customizable nanotherapies, but substantial questions about dosing, biodistribution, immune effects, manufacturing, and safety must still be answered.
The study illustrates how nanotechnology, RNA biology, cancer pharmacology, and oral medicine are converging around a disease in urgent need of new options. By combining a genetic therapy with a small-molecule drug in a single carrier, the researchers are attempting to make cancer treatment more adaptable than conventional single-agent strategies. The results do not yet represent a treatment available to patients, but they provide preclinical evidence that an LNP can simultaneously restore a damaged tumor-suppressor function, deliver a second anticancer compound, and reshape the immune landscape of oral cancer.
Subject of Research: Animals
Article Title: Lipid Nanoparticle Co-Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy
News Publication Date: 14 July 2026
Web References: https://doi.org/10.1002/adma.73721; https://mitchell-lab.seas.upenn.edu/about/; https://www.dental.upenn.edu/faculty/anh-d-le/
References: Advanced Materials, DOI: 10.1002/adma.73721
Keywords: Oral squamous cell carcinoma, oral cancer, lipid nanoparticles, mRNA therapy, p53, ciclopirox, cancer immunotherapy, chemoimmunotherapy, drug delivery, nanomedicine
